Sodium 2-hydroxylinoleate | |
---|---|
Trade Name | |
Orphan Indication | Neuroblastoma |
EU Market Approval | EU |
EU Designation Date | 2015-04-24 00:00:00 |
Sponsor | Ability Pharmaceuticals SL |
Related Access Program
South Plains Oncology Consortium – Recurrent Neuroblastoma
Catalyst Pharmaceuticals, Inc. – Downbeat Nystagmus
South Plains Oncology Consortium – Neuroblastoma
British Columbia Cancer Agency – Neuroblastoma
South Plains Oncology Consortium – Neuroblastoma
Children’s Hospital of Philadelphia – Neuroblastoma
University of California, San Francisco – Neuroblastoma
Jubilant DraxImage Inc. – Neuroblastoma
Children’s Hospital Medical Center, Cincinnati – Neuroblastoma
Apeiron Biologics AG – Neuroblastoma